P
Paul D. Smith
Researcher at AstraZeneca
Publications - 218
Citations - 12256
Paul D. Smith is an academic researcher from AstraZeneca. The author has contributed to research in topics: Selumetinib & Cancer. The author has an hindex of 53, co-authored 207 publications receiving 10843 citations. Previous affiliations of Paul D. Smith include National Institutes of Health & Institute of Cancer Research.
Papers
More filters
Journal ArticleDOI
DRAM, a p53-Induced Modulator of Autophagy, Is Critical for Apoptosis
Diane Crighton,Simon Wilkinson,Jim O'Prey,Nelofer Syed,Paul D. Smith,Paul R. Harrison,Milena Gasco,Ornella Garrone,Tim Crook,Kevin M. Ryan +9 more
TL;DR: DRAM (damage-regulated autophagy modulator), a p53 target gene encoding a lysosomal protein that induces macroautophagy, is described as an effector of p53-mediated death and its relationship to p53 function and damage-induced programmed cell death is highlighted.
Journal ArticleDOI
Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study
Pasi A. Jänne,Alice T. Shaw,José Rodrigues Pereira,Gaelle Jeannin,Johan Vansteenkiste,Carlos H. Barrios,Fabio Franke,Lynda Grinsted,Victoria Zazulina,Paul D. Smith,Ian C. Smith,Lucio Crinò +11 more
TL;DR: A prospective, randomised, phase 2 trial to assess selumetinib plus docetaxel in previously treated patients with advanced KRAS-mutant NSCLC found promising efficacy, albeit with a higher number of adverse events.
Journal Article
Gene Expression Profiling of Alveolar Rhabdomyosarcoma with cDNA Microarrays
Javed Khan,Richard Simon,Michael L. Bittner,Yi Chen,Stephen B. Leighton,Thomas Pohida,Paul D. Smith,Yuan Jiang,Gerald C. Gooden,Jeffrey M. Trent,Paul S. Meltzer +10 more
TL;DR: The use of cDNA microarrays containing 1238 cDNAs to investigate the gene expression profile of a group of seven alveolar rhabdomyosarcoma (ARMS) cell lines determined that ARMS cells show a consistent pattern of gene expression, which allows the cells to be clustered together.
Journal ArticleDOI
MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road.
TL;DR: How some of the systems-level properties of the ERK pathway present a challenge for the success of MEK1 and MEK2 inhibitors is considered, as well as mechanisms of resistance to these inhibitors, and their clinical progress is reviewed.
Journal ArticleDOI
AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models
Barry R. Davies,Armelle Logie,Jennifer S. McKay,Paul D. Martin,Samantha J. Steele,Richard O. Jenkins,Mark Cockerill,Sue Cartlidge,Paul D. Smith +8 more
TL;DR: In this paper, the potential of AZD6244 in combination with cytotoxic drugs was evaluated in mice bearing SW-620 xenografts, and the results indicated that enhanced antitumor efficacy can be obtained by combining AZD-6244 with either irinotecan or docetaxel.